MIP Enters into Agreement with Sanofi-Aventis for Development of a Selective Separation Polymer for Biopharmaceuticals
News Jan 16, 2009
MIP Technologies AB announces that it has entered into a collaboration with sanofi-aventis for the development of new molecularly imprinted polymers (MIPs) for the analysis of pharmacologically active peptides from plasma samples.
MIP Technologies will use a number of its patented molecular imprinting methods in the development of the polymers. The use of MIPs for selective recognition of peptides and proteins is a novel area that will open up the technology to numerous applications in the diagnostic, pharmaceutical and biopharmaceutical industries.
“This collaboration with sanofi-aventis is both exciting and challenging,” said Dr Anthony Rees, CEO at MIP Technologies. “We are looking to move into the development of peptide-selective MIPs which represents a valuable piece of the separations market and has applications in analytical, preparative and process scale separations. Peptide-selective MIPs are particularly relevant for MIP Technologies since we hold important patents in this area. The added benefit of being able to address a large, new global market for molecularly imprinted polymers represents a significant commercial opportunity for the company.”
Sanofi-aventis will have exclusive access for use of the polymer in the analysis of proprietary peptide candidates, while MIP Technologies will retain the rights to use the polymers for other applications.
The incorporation of the polymer into the sanofi-aventis analytical methods will make use of separation cartridges which will be provided through MIP Technologies’ exclusive partnership in analytical products with Supelco, a division of Sigma Aldrich. MIP material developed during the collaboration may also be usable for selective peptide purification at preparative or process scale. Financial terms were not disclosed.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019